Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence
Completed · Not applicable
Conditions studied: Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage III Breast Cancer AJCC v7
In brief
This phase II trial studies how well telehealth works in improving adherence to endocrine (anti-estrogen) therapy in participants with estrogen receptor and/or progesterone receptor positive (hormone receptor positive) stage 0-III breast cancer who have underwent surgery. Telehealth is an approach to care that uses digital information and communication tools to manage health and well-being. Participants interact with their health care providers via a video chat on a computer or smart phone. Telehealth may help identify the effects of treatment on participants with breast cancer who have underwent surgery.
Key facts
- Study ID
- NCT04054557
- Run by
- Thomas Jefferson University
- People needed
- 305
- Starts
- 2019-07-31
- Expected to finish
- 2024-12-06
- Last updated by the study team
- 2026-02-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- • Signed informed consent obtained prior to any study specific assessments and procedures
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Women or men diagnosed with stage 0-III hormone receptor positive (estrogen receptor positive [ER] and /or progesterone receptor [PR] positive) breast cancer
- Staging for eligibility should utilize the most recent American Joint Committee on Cancer (AJCC) breast cancer staging version
- Patients (Pts) must have undergone breast surgery for their diagnosis of breast cancer
- Adjuvant endocrine therapy has been prescribed by their treating physician
- Patients may receive concurrent adjuvant radiation therapy plus endocrine therapy in the post-operative setting
- Have a cell phone with text messaging ability
- Have access to a computer, tablet, or smart phone to complete electronic surveys
- Patient must be willing to setup an online Jefferson MyChart account
- Patients who have been on endocrine therapy for more than 4 years
You may not qualify if…
- Pts with stage IV metastatic breast cancer
- Patients unable to participate in patient portal communication (e.g. do not have either a smart phone, laptop, access to a computer and/ or access to a device with a webcam)
- Pts who are non-English speaking and English illiterate
Where it is running
- Jefferson Health - South Jersey — Washington Township, New Jersey, United States
- Thomas Jefefrson University — Philadelphia, Pennsylvania, United States
- Methodist Hospital — Philadelphia, Pennsylvania, United States
- Jefferson Health - Northeast — Torresdale, Pennsylvania, United States
- Jefferson Health - Asplundh Cancer Pavilion — Willow Grove, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.